A possible mechanism for hepatotoxicity induced by BIRB-796, an orally active p38 mitogen-activated protein kinase inhibitor

Journal of Applied Toxicology

Volumn 31, Issue 7, 2011, Pages 671-677

  Iwano, Shunsuke ^a   Asaoka, Yoshiji ^a   Akiyama, Hideo ^a   Takizawa, Satoko ^a   Nobumasa, Hitoshi ^a   Hashimoto, Hisashi ^a   Miyamoto, Yohei ^a  

^a TORAY INDUSTRIES INC   (Japan)

Author keywords

BIRB 796; DNA microarray; Hepatotoxicity; P38 MAPK; Toxicogenomics

Indexed keywords

DORAMAPIMOD; GLUTATHIONE; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DNA MICROARRAY; DRUG MECHANISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CHROMATOGRAPHY, LIQUID; DOWN-REGULATION; DRUG-INDUCED LIVER INJURY; GLUTATHIONE; HUMANS; MALE; MICE; MICE, INBRED ICR; MICROSOMES, LIVER; NAPHTHALENES; NF-E2-RELATED FACTOR 2; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRAZOLES; RNA, MESSENGER; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TOXICOGENETICS; UP-REGULATION;

EID: 80054990842     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1622     Document Type: Article

References (26)

1. Barry J, Kirby B. 2004. Novel biologic therapies for psoriasis. Expert Opin. Biol. Ther. 4: 975-987.
2. Branger J, van den Blink B, Weijer S, Madwed J, Bos CL, Gupta A, Yong CL, Polmar SH, Olszyna DP, Hack CE, van Deventer SJ, Peppelenbosch MP, van der Poll T. 2002. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J. Immunol. 168: 4070-4077.
3. Buckpitt A, Boland B, Isbell M, Morin D, Shultz M, Baldwin R, Chan K, Karlsson A, Lin C, Taff A, West J, Fanucchi M, Van Winkle L, Plopper C. 2002. Naphthalene-induced respiratory tract toxicity: metabolic mechanisms of toxicity. Drug Metab. Rev. 34: 791-820.
4. Dinarello CA. 1991. Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr. Opin. Immunol. 3: 941-948.
5. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. 2004. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17: 3-16.
6. Feldmann M, Brennan FM, Maini RN. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14: 397-440.
7. Foster ML, Halley F, Souness JE. 2000. Potential of p38 inhibitors in the treatment of rheumatoid arthritis. Drug News Perspect. 13: 488-497.
8. Franklin R, Plopper C, Buckpitt A. 1993. Naphthalene and 2-methylnaphthalene-induced pulmonary bronchiolar epithelial cell necrosis: metabolism and relationship toxicity. In Metabolic Activation and Toxicity of Chemical Agents to Lung Tissue and Cells, Gram T (ed.). Pergamon Press: New York; 123-144.
9. Fukushima T, Kikkawa R, Hamada Y, Horii I. 2006. Genomic cluster and network analysis for predictive screening for hepatotoxicity. J. Toxicol. Sci. 31: 419-432.
10. Goldring CE, Kitteringham NR, Elsby R, Randle LE, Clement YN, Williams DP, McMahon M, Hayes JD, Itoh K, Yamamoto M, Park BK. 2004. Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice. Hepatology 39: 1267-1276.
11. Guo L, Lobenhofer EK, Wang C, Shippy R, Harris SC, Zhang L, Mei N, Chen T, Herman D, Goodsaid FM, Hurban P, Phillips KL, Xu J, Deng X, Sun YA, Tong W, Dragan YP, Shi L. 2006. Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat. Biotechnol. 24: 1162-1169.
12. Heijne WH, Slitt AL, van Bladeren PJ, Groten JP, Klaassen CD, Stierum RH, van Ommen B. 2004. Bromobenzene-induced hepatotoxicity at the transcriptome level. Toxicol. Sci. 79: 411-422.
13. Klinkhoff A. 2004. Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs 64: 1267-1283.
14. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746.
15. Levine DM, Haynor DR, Castle JC, Stepaniants SB, Pellegrini M, Mao M, Johnson JM. 2006. Pathway and gene-set activation measurement from mRNA expression data: the tissue distribution of human pathways. Genome Biol. 7: R93.
16. Miller NE, Thomas D, Billings RE. 1990. Bromobenzene metabolism in vivo and in vitro. The mechanism of 4-bromocatechol formation. Drug Metab. Dispos. 18: 304-308.
17. Nagino K, Nomura O, Takii Y, Myomoto A, Ichikawa M, Nakamura F, Higasa M, Akiyama H, Nobumasa H, Shiojima S, Tsujimoto G. 2006. Ultrasensitive DNA chip: gene expression profile analysis without RNA amplification. J. Biochem. 139: 697-703.
18. Nguyen T, Nioi P, Pickett CB. 2009. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284: 13291-13295.
19. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. 2008. The current state of serum biomarkers of hepatotoxicity. Toxicology 245: 194-205.
20. Pumford NR, Halmes NC, Hinson JA. 1997. Covalent binding of xenobiotics to specific proteins in the liver. Drug Metab. Rev. 29: 39-57.
21. Regan J, Breitfelder S, Cirillo P, Gilmore T, Graham AG, Hickey E, Klaus B, Madwed J, Moriak M, Moss N, Pargellis C, Pav S, Proto A, Swinamer A, Tong L, Torcellini C. 2002. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J. Med. Chem. 45: 2994-3008.
22. Regan J, Capolino A, Cirillo PF, Gilmore T, Graham AG, Hickey E, Kroe RR, Madwed J, Moriak M, Nelson R, Pargellis CA, Swinamer A, Torcellini C, Tsang M, Moss N. 2003. Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]urea (BIRB 796). J. Med. Chem. 46: 4676-4686.
23. Schreiber S, Feagan B, D'Haens G, Colombel JF, Geboes K, Yurcov M, Isakov V, Golovenko O, Bernstein CN, Ludwig D, Winter T, Meier U, Yong C, Steffgen J. 2006. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 4: 325-334.
24. Wheelock AM, Boland BC, Isbell M, Morin D, Wegesser TC, Plopper CG, Buckpitt AR. 2005. In vivo effects of ozone exposure on protein adduct formation by 1-nitronaphthalene in rat lung. Am. J. Respir. Cell Mol. Biol. 33: 130-137.
25. Zheng J, Ma L, Xin B, Olah T, Humphreys WG, Zhu M. 2006. Screening and identification of GSH-trapped reactive metabolites using hybrid triple quadruple linear ion trap mass spectrometry. Chem. Res. Toxicol. 20: 757-766.
26. Zhou S, Chan E, Duan W, Huang M, Chen YZ. 2005. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab. Rev. 37: 41-213.